News
AXDX
--
0.00%
--
Antimicrobial Susceptibility Testing Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2027
Jan 21, 2021 (Heraldkeepers) -- Meticulous Research(R)- leading global market research company published a research report titled "Antimicrobial...
Heraldkeepers · 1d ago
Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus
Accelerate Diagnostics (AXDX) added 45 live instruments in Q4, resulting in a year-end total of 268 revenue-generating instruments in the U.S.The company expects Q4 total revenue to be ~$3.1M, vs.
Seekingalpha · 01/12 11:34
BRIEF-Accelerate Diagnostics Sees Q4 2020 Revenue About $3.1 Million
reuters.com · 01/12 11:12
Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
, /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below.
PR Newswire - PRF · 01/12 11:00
Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
TUCSON, Ariz., Jan. 12, 2021 /PRNewswire via COMTEX/ -- TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today...
PR Newswire - PRF · 01/12 11:00
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 01/08 20:30
Downtrend Call Working As Accelerate Diagn Stock Falls 49.9% (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 5 months, Accelerate Diagn has returned 49.87% as of today's recent price of $7.47.
Comtex SmarTrend(R) · 12/30/2020 18:18
48.6% Return Seen to Date on SmarTrend Accelerate Diagn Call (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 5 months, Accelerate Diagn has returned 48.59% as of today's recent price of $7.66.
Comtex SmarTrend(R) · 12/23/2020 05:24
51.8% Return Seen to Date on SmarTrend Accelerate Diagn Call (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 5 months, Accelerate Diagn has returned 51.81% as of today's recent price of $7.18.
Comtex SmarTrend(R) · 12/16/2020 05:31
Is AXDX A Good Stock To Buy Now?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and no...
Insider Monkey · 12/14/2020 12:07
Accelerate Diagn Shares Down 50.5% Since SmarTrend's Sell Call (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 4 months, Accelerate Diagn has returned 50.47% as of today's recent price of $7.38.
Comtex SmarTrend(R) · 12/08/2020 18:10
Global Bloodstream Infection Testing Market (2020 to 2024) - Featuring Abbott Laboratories, Accelerate Diagnostics and Becton Among Others - ResearchAndMarkets.com
The "Global Bloodstream Infection Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
BusinessWire · 12/07/2020 08:24
Global Bloodstream Infection Testing Market (2020 to 2024) - Featuring Abbott Laboratories, Accelerate Diagnostics and Becton Among Others - ResearchAndMarkets.com
The "Global Bloodstream Infection Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
BusinessWire · 12/07/2020 08:24
Downtrend Call Working As Accelerate Diagn Stock Falls 47.5% (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 4 months, Accelerate Diagn has returned 47.52% as of today's recent price of $7.82.
Comtex SmarTrend(R) · 12/01/2020 05:20
Downtrend Call Working As Accelerate Diagn Stock Falls 47.5% (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 4 months, Accelerate Diagn has returned 47.52% as of today's recent price of $7.82.
Comtex SmarTrend(R) · 12/01/2020 05:20
Accelerate Diagn Down 44.6% Since SmarTrend Downtrend Call (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 4 months, Accelerate Diagn has returned 44.63% as of today's recent price of $8.25.
Comtex SmarTrend(R) · 11/23/2020 18:09
Accelerate Diagn Down 44.6% Since SmarTrend Downtrend Call (AXDX)
SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on July 27th, 2020 at $14.90. In approximately 4 months, Accelerate Diagn has returned 44.63% as of today's recent price of $8.25.
Comtex SmarTrend(R) · 11/23/2020 18:09
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Just Reported, And Analysts Assigned A US$15.00 Price Target
The third-quarter results for Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were released last week, making it a good...
Simply Wall St. · 11/07/2020 12:53
Accelerate Diagnostics Reports Third Quarter 2020 Financial Results
, /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended .
PR Newswire - PRF · 11/05/2020 21:29
Accelerate Diagnostics Reports Third Quarter 2020 Financial Results
, /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended .
PR Newswire - PRF · 11/05/2020 21:29
Webull provides a variety of real-time AXDX stock news. You can receive the latest news about Accelerate through multiple platforms. This information may help you make smarter investment decisions.
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
More